CL2021002296A1 - Compuestos tricíclicos condensados útiles como agentes anticancerígenos - Google Patents
Compuestos tricíclicos condensados útiles como agentes anticancerígenosInfo
- Publication number
- CL2021002296A1 CL2021002296A1 CL2021002296A CL2021002296A CL2021002296A1 CL 2021002296 A1 CL2021002296 A1 CL 2021002296A1 CL 2021002296 A CL2021002296 A CL 2021002296A CL 2021002296 A CL2021002296 A CL 2021002296A CL 2021002296 A1 CL2021002296 A1 CL 2021002296A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds useful
- anticancer agents
- tricyclic compounds
- condensed tricyclic
- condensed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La memoria descriptiva se refiere a compuestos de Fórmula (A) y sales farmacéuticamente aceptables de los mismos. La memoria descriptiva también se refiere a procesos e intermedios utilizados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813885P | 2019-03-05 | 2019-03-05 | |
| US201962951146P | 2019-12-20 | 2019-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002296A1 true CL2021002296A1 (es) | 2022-04-29 |
Family
ID=69740367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002296A CL2021002296A1 (es) | 2019-03-05 | 2021-09-02 | Compuestos tricíclicos condensados útiles como agentes anticancerígenos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220204527A1 (es) |
| EP (1) | EP3935060B1 (es) |
| JP (1) | JP7453989B2 (es) |
| KR (1) | KR20210135539A (es) |
| CN (1) | CN113508118B (es) |
| AU (1) | AU2020231045B2 (es) |
| BR (1) | BR112021017408A2 (es) |
| CA (1) | CA3131156A1 (es) |
| CL (1) | CL2021002296A1 (es) |
| CO (1) | CO2021012381A2 (es) |
| CR (1) | CR20210504A (es) |
| DO (1) | DOP2021000183A (es) |
| EC (1) | ECSP21073246A (es) |
| IL (1) | IL285761B1 (es) |
| JO (1) | JOP20210241A1 (es) |
| MA (1) | MA55198A (es) |
| MX (1) | MX2021010674A (es) |
| PE (1) | PE20220140A1 (es) |
| SG (1) | SG11202109451TA (es) |
| TW (1) | TW202100532A (es) |
| UY (1) | UY38602A (es) |
| WO (1) | WO2020178282A1 (es) |
| ZA (1) | ZA202106192B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| US11453683B1 (en) | 2019-08-29 | 2022-09-27 | Mirati Therapeutics, Inc. | KRas G12D inhibitors |
| EP4034123A4 (en) | 2019-09-24 | 2023-11-01 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| MX2022005053A (es) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Inhibidores de peque?as moleculas de mutante g12c de kras. |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| UA128806C2 (uk) | 2019-12-11 | 2024-10-23 | Елі Ліллі Енд Компані | Інгібітори kras g12c |
| IL294048A (en) | 2019-12-20 | 2022-08-01 | Mirati Therapeutics Inc | sos1 inhibitors |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| CN114437107A (zh) * | 2020-11-06 | 2022-05-06 | 江苏先声药业有限公司 | 哌嗪类化合物及其应用 |
| CN114539286B (zh) * | 2020-11-24 | 2024-02-02 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| TW202235082A (zh) | 2020-12-04 | 2022-09-16 | 美商美國禮來大藥廠 | Ｋｒａｓ ｇ１２ｃ抑制劑 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| BR112023020773A2 (pt) * | 2021-04-08 | 2024-01-30 | Genentech Inc | Compostos, composição farmacêutica, métodos para tratar câncer, para regular a atividade de uma proteína mutante, para inibir a proliferação de uma população celular, para preparar uma proteína mutante e para inibir metástase de tumor, uso de um composto e processo para sintetizar um composto |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| EP4421076A1 (en) | 2021-10-22 | 2024-08-28 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| WO2023072297A1 (zh) * | 2021-11-01 | 2023-05-04 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
| WO2023126822A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
| WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024213699A1 (en) | 2023-04-14 | 2024-10-17 | Astrazeneca Ab | Combinations of kras inhibitor and atr inhibitor for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090318412A1 (en) * | 2006-07-11 | 2009-12-24 | Takahiro Matsumoto | Tricyclic heterocyclic compound and use thereof |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
| GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| AR111776A1 (es) * | 2017-05-11 | 2019-08-21 | Astrazeneca Ab | Heteroarilos inhibidores de las proteínas ras mutantes de g12c |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
-
2020
- 2020-03-03 MA MA055198A patent/MA55198A/fr unknown
- 2020-03-03 SG SG11202109451TA patent/SG11202109451TA/en unknown
- 2020-03-03 US US17/436,137 patent/US20220204527A1/en active Pending
- 2020-03-03 KR KR1020217031298A patent/KR20210135539A/ko active Search and Examination
- 2020-03-03 JP JP2021552640A patent/JP7453989B2/ja active Active
- 2020-03-03 CN CN202080018236.1A patent/CN113508118B/zh active Active
- 2020-03-03 CR CR20210504A patent/CR20210504A/es unknown
- 2020-03-03 PE PE2021001444A patent/PE20220140A1/es unknown
- 2020-03-03 MX MX2021010674A patent/MX2021010674A/es unknown
- 2020-03-03 IL IL285761A patent/IL285761B1/en unknown
- 2020-03-03 EP EP20708488.0A patent/EP3935060B1/en active Active
- 2020-03-03 AU AU2020231045A patent/AU2020231045B2/en active Active
- 2020-03-03 WO PCT/EP2020/055551 patent/WO2020178282A1/en active Application Filing
- 2020-03-03 CA CA3131156A patent/CA3131156A1/en active Pending
- 2020-03-03 BR BR112021017408A patent/BR112021017408A2/pt unknown
- 2020-03-03 JO JOP/2021/0241A patent/JOP20210241A1/ar unknown
- 2020-03-05 UY UY0001038602A patent/UY38602A/es unknown
- 2020-03-05 TW TW109107275A patent/TW202100532A/zh unknown
-
2021
- 2021-08-26 ZA ZA2021/06192A patent/ZA202106192B/en unknown
- 2021-09-01 DO DO2021000183A patent/DOP2021000183A/es unknown
- 2021-09-02 CL CL2021002296A patent/CL2021002296A1/es unknown
- 2021-09-22 CO CONC2021/0012381A patent/CO2021012381A2/es unknown
- 2021-10-01 EC ECSENADI202173246A patent/ECSP21073246A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3935060A1 (en) | 2022-01-12 |
| UY38602A (es) | 2020-09-30 |
| JP7453989B2 (ja) | 2024-03-21 |
| PE20220140A1 (es) | 2022-01-27 |
| MA55198A (fr) | 2022-01-12 |
| AU2020231045B2 (en) | 2023-03-16 |
| MX2021010674A (es) | 2021-09-28 |
| TW202100532A (zh) | 2021-01-01 |
| CN113508118A (zh) | 2021-10-15 |
| IL285761B1 (en) | 2024-08-01 |
| DOP2021000183A (es) | 2021-09-30 |
| US20220204527A1 (en) | 2022-06-30 |
| ZA202106192B (en) | 2022-08-31 |
| CN113508118B (zh) | 2024-07-19 |
| JP2022523981A (ja) | 2022-04-27 |
| CA3131156A1 (en) | 2020-09-10 |
| EP3935060C0 (en) | 2023-11-15 |
| AU2020231045A1 (en) | 2021-10-28 |
| KR20210135539A (ko) | 2021-11-15 |
| CR20210504A (es) | 2022-02-08 |
| IL285761A (en) | 2021-10-31 |
| ECSP21073246A (es) | 2021-11-30 |
| SG11202109451TA (en) | 2021-09-29 |
| EP3935060B1 (en) | 2023-11-15 |
| WO2020178282A1 (en) | 2020-09-10 |
| BR112021017408A2 (pt) | 2022-01-18 |
| JOP20210241A1 (ar) | 2023-01-30 |
| CO2021012381A2 (es) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21073246A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| UY38070A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
| CO2019008941A2 (es) | Moduladores del receptor de estrógeno | |
| CL2022000201A1 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| CL2016003329A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| ECSP24028270A (es) | Compuestos espirocíclicos | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| ECSP22049160A (es) | Derivados de bencimidazol | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| CL2021000184A1 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
| CL2017002605A1 (es) | Derivados de indol | |
| EA202192366A1 (ru) | Конденсированные трициклические соединения, применимые в качестве противораковых средств |